CompanyDrug

Hotgen Biotech’s Novel Treg-Targeting Bispecific Antibody SGT003 Clears NMPA Filing Hurdle

CompanyDeals

Haisco Pharma Licenses Nav1.8 Pain Program to AbbVie in $745M Deal, Retaining Greater China Rights

FDA Accepts NDA for Telix's Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026
CompanyDrug

FDA Accepts NDA for Telix’s Pixclara (TLX101-Px) Glioma Imaging Agent, Decision Expected September 2026

GSK's B7-H4 ADC Mocertatug Rezetecan Shows 62-67% Response Rates in Phase I Ovarian and Endometrial Cancer Trials
CompanyDrug

GSK’s B7-H4 ADC Mocertatug Rezetecan Shows 62-67% Response Rates in Phase I Ovarian and Endometrial Cancer Trials

Merck KGaA Closes Acquisition of JSR Life Sciences' Chromatography Business, Bolstering Antibody Purification Portfolio
CompanyDeals

Merck KGaA Closes Acquisition of JSR Life Sciences’ Chromatography Business, Bolstering Antibody Purification Portfolio

CompanyDeals

Boehringer Ingelheim and BioNTech Launch Phase Ib/II Trial of Novel T-Cell Engager and Bispecific Antibody Combo for ES-SCLC

CompanyMedical Device

Gaush Meditech Secures CE Mark for Corneal Confocal Microscope, Paving Way for EU Commercial Launch

CompanyDeals

Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets

Nanjing Pharma Launches $110M Corporate Fund to Acquire Controlling Stakes in Datsing Bio and Kejian Tech
Others

Nanjing Pharma Launches $110M Corporate Fund to Acquire Controlling Stakes in Datsing Bio and Kejian Tech

CompanyDeals

Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology

CompanyDeals

Sun Pharma in Advanced Talks to Acquire Organon for $12 Billion, Bolstering Women’s Health Portfolio

CompanyDrug

Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer